OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
WEED58

Canopy Growth Corp

PharmaceuticalsVerified

Canopy Growth Corp has a debt-to-equity ratio of 0.67 and a current ratio of 3.12, indicating moderate leverage and strong short-term liquidity. However, the company's cash and equivalents amount to only CAD 130,000, which is significantly lower than its long-term debt of CAD 325,267,000, suggesting a liquidity risk. The company's profitability metrics are weak, with a return on equity of -1.2276 and a return on assets of -0.6518, both well below the industry median for pharmaceutical companies. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. Canopy Growth Corp's revenue is concentrated in a single business segment, cannabis cultivation and sales, with no disclosed geographic diversification. This concentration increases exposure to regulatory and market risks in the cannabis industry. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. Analysts have provided a mean price target of CAD 2.36 and a median price target of CAD 1.80, with a mean recommendation of 2.83, indicating a mixed outlook. The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt underscores the company's financial vulnerability. Recent events include a continued focus on cost reduction and operational efficiency, as disclosed in the company's latest financial filings. No major new product launches or strategic acquisitions were reported in the most recent quarter.

30-day price · WEED+0.01 (+0.7%)
Low$1.31High$2.07Close$1.51As of25 May, 00:00 UTC
Profile
CompanyCanopy Growth Corp
TickerWEED.TO
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Canopy Growth Corp is a Canadian cannabis company that cultivates, produces, and sells cannabis and cannabis-derived products for medical and recreational use.

Classification. Canopy Growth Corp is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.

Canopy Growth Corp has a debt-to-equity ratio of 0.67 and a current ratio of 3.12, indicating moderate leverage and strong short-term liquidity. However, the company's cash and equivalents amount to only CAD 130,000, which is significantly lower than its long-term debt of CAD 325,267,000, suggesting a liquidity risk. The company's profitability metrics are weak, with a return on equity of -1.2276 and a return on assets of -0.6518, both well below the industry median for pharmaceutical companies. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets. Canopy Growth Corp's revenue is concentrated in a single business segment, cannabis cultivation and sales, with no disclosed geographic diversification. This concentration increases exposure to regulatory and market risks in the cannabis industry. The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent fiscal year. Analysts have provided a mean price target of CAD 2.36 and a median price target of CAD 1.80, with a mean recommendation of 2.83, indicating a mixed outlook. The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt underscores the company's financial vulnerability. Recent events include a continued focus on cost reduction and operational efficiency, as disclosed in the company's latest financial filings. No major new product launches or strategic acquisitions were reported in the most recent quarter.
Key takeaways
  • Canopy Growth Corp has a weak return on equity and return on assets, indicating poor profitability.
  • The company's liquidity is constrained by low cash reserves relative to its debt.
  • Revenue is concentrated in a single business segment, increasing exposure to industry-specific risks.
  • Analysts have a mixed outlook, with a mean price target of CAD 2.36 and a median price target of CAD 1.80.
  • The company faces a medium liquidity risk and a low dilution risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCAD
Revenue$269.0M
Gross profit$81.5M
Operating income-$94.8M
Net income-$598.1M
R&D
SG&A
D&A
SBC
Operating cash flow-$165.8M
CapEx-$11.3M
Free cash flow-$572.3M
Total assets$917.7M
Total liabilities$430.5M
Total equity$487.2M
Cash & equivalents$130.0k
Long-term debt$325.3M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$487.2M
Net cash-$325.1M
Current ratio3.1
Debt/Equity0.7
ROA-65.2%
ROE-1.2%
Cash conversion28.0%
CapEx/Revenue-4.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricWEEDActivity
Op margin-35.2%2.4% medp25 -91.8% · p75 12.5%below median
Net margin-222.4%1.2% medp25 -98.4% · p75 10.4%bottom quartile
Gross margin30.3%45.6% medp25 29.8% · p75 66.7%below median
CapEx / revenue-4.2%-5.2% medp25 -15.8% · p75 -1.7%above median
Debt / equity67.0%9.3% medp25 0.1% · p75 43.8%top quartile
Observations
IR observations
Mean price target2.36 CAD
Median price target1.80 CAD
High price target5.00 CAD
Low price target1.40 CAD
Mean recommendation2.83 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count2.00
Hold count3.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate-0.47 CAD
Last actual EPS-5.56 CAD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-25 03:44 UTC#d92addde
Source: analysis-pipeline (hybrid)Generated: 2026-05-30 00:28 UTCJob: f149531d